Sofinnova Investments, Inc. Janux Therapeutics, Inc. Transaction History
Sofinnova Investments, Inc.
- $1.23 Billion
- Q4 2024
A detailed history of Sofinnova Investments, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Sofinnova Investments, Inc. holds 253,262 shares of JANX stock, worth $8.06 Million. This represents 1.1% of its overall portfolio holdings.
Number of Shares
253,262
Previous 164,770
53.71%
Holding current value
$8.06 Million
Previous $7.49 Million
81.15%
% of portfolio
1.1%
Previous 0.71%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
229Shares Held
55.2MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$330 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$113 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$112 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$97.5 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$74.6 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.33B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...